Patient Selection for Metabolic Surgery

  • Jose Guido Correa de AraujoJr.
  • Josemberg Marins Campos
  • Renata Paiva Barbosa
  • Maira Danielle Gomes
  • Álvaro Antônio Bandeira Ferraz


The world diabetes pandemic, closely linked to the obesity pandemic, is increasingly demanding attention from the scientific community to improve treatment results and ameliorate metabolic complications, cardiometabolic risk factors and overall morbidity and mortality in diabetic patients. Medical treatment and lifestyle changes are the traditional approach for type 2 diabetes mellitus (T2DM), although poor results in modification of main endpoints for glycaemic control are achieved with this approach in most patients on the long term because of the progressive nature of the disease. In the past decades, reports on excellent control of metabolic parameters despite weight loss have risen great interest in bariatric surgery as a treatment for T2DM. Whereas weight loss no doubt plays a main role on the improvement of metabolic parameters in obese individuals submitted to weight loss procedures, the findings of significant control in metabolic parameters on early postoperative periods, despite insignificant weight loss, and the understanding of the physiopathology of enteroendocrine changes leading to excellent glycaemic control following bariatric procedures have stimulated research on the surgical treatment of T2DM, especially in mild obesity patients. Questions remain as to which diabetic patients can benefit of bariatric surgery to improve metabolic parameters, and whether patient selection for metabolic surgery can rely on the same diagnostic tools used to select nondiabetic patients for weight loss surgery. Thorough preoperative evaluation and adequate patient selection is key to success in surgery, and this section will focus on the adequate selection of patients for metabolic surgery in the range of obesity.


Obesity Metabolic syndrome Bariatric surgery Metabolic surgery Gastric bypass RYBG Diabetes Type 2 diabetes mellitus Patient selection Glycaemic control 


  1. 1.
    Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.CrossRefGoogle Scholar
  2. 2.
    National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases: National Diabetes Statistics, 2014.
  3. 3.
    Conway B, Miller RG, Costacou T, Fried L, Kelsey S, Evans RW, Orchard TJ. Adiposity and mortality in type 1 diabetes. Int J Obes. 2009;33(7):796–805.CrossRefGoogle Scholar
  4. 4.
    Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract. 2006;60(1):48–56.CrossRefGoogle Scholar
  5. 5.
    Cugnet-Anceau C, Bauduceau B. Glycaemic control and cardiovascular morbid-mortality: the contribution of the 2008 studies. Ann Endocrinol. 2009;70(1):48–54.CrossRefGoogle Scholar
  6. 6.
    Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59.CrossRefGoogle Scholar
  7. 7.
    Chan JC, Malik V, Jia W, Kadowaski T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors and pathophysiology. JAMA. 2009;301:2129–40.CrossRefGoogle Scholar
  8. 8.
    Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia. 2002;45:S23–8.CrossRefGoogle Scholar
  9. 9.
    Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–7.CrossRefGoogle Scholar
  10. 10.
    Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20.CrossRefGoogle Scholar
  11. 11.
    UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRefGoogle Scholar
  12. 12.
    Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric Surgery. A systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefGoogle Scholar
  13. 13.
    Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.CrossRefGoogle Scholar
  14. 14.
    Cummings DE, Cohen RV. Bariatric/Metabolic surgery to treat type 2 diabetes in patients with a BMI < 35kg/m2. Diabetes Care. 2016;39:924–33.CrossRefGoogle Scholar
  15. 15.
    Cohen R, Pinheiro JS, Correa JL, Schiavon CA. Laparoscopic Roux-en-Y gastric bypass for BMI < 35m2: a tailored approach. Surg Obes Relat Dis. 2006;2:401–4.CrossRefGoogle Scholar
  16. 16.
    De Sá VC, Ferraz AA, Campos JM, Ramos AC, Araujo JG, Ferraz EM. Gastric bypass in the treatment of type 2 diabetes in patients with a BMI of 30–35Kg/m2. Obes Surg. 2011;21:283–7.CrossRefGoogle Scholar
  17. 17.
    Shimizu H, Timratana P, Schauer PR. Review of metabolic surgery for type 2 diabetes and body mass index less than 35%. J Obes. 2012;2012:147256.CrossRefGoogle Scholar
  18. 18.
    Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery vs. intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.CrossRefGoogle Scholar
  19. 19.
    Ikramuddin S, Korner J, Lee W, Connet J. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension and hyperlipidemia. The Diabetes Surgery Study Randomized clinical trial. JAMA. 2013;309(21):2240–9.CrossRefGoogle Scholar
  20. 20.
    Pok EH, Lee WJ. Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus. World J Gastroenterol. 2014;20(39):14315–28.CrossRefGoogle Scholar
  21. 21.
    Birkmeyer NJ, Dimick JB, Share D. Hospital complication rates with bariatric surgery in Michigan. JAMA. 2010;304(4):435–42.CrossRefGoogle Scholar
  22. 22.
    Nguyen NT, Masoomi H, Magno CP, et al. Trends in use of bariatric surgery, 2003–2008. J Am Coll Surg. 2011;213(2):261–6.CrossRefGoogle Scholar
  23. 23.
    Sjӧstrӧm L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311:2297–304.CrossRefGoogle Scholar
  24. 24.
    Mingrone G, Panuzi S, de Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: a 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964–73.CrossRefGoogle Scholar
  25. 25.
    Panuzi S, De Gaetano A, Carnicelli A, Mingrone G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg. 2015;261:559–467.Google Scholar
  26. 26.
    Yu H, Di J, Bao Y, Zhang P, Zhang L, Tu Y, Han X, Jia W. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y Gastric bypass surgery in Chinese patients with a body mass index less than 35Kg/m2. Surg Obes Relat Dis. 2015;11(1):6–11.CrossRefGoogle Scholar
  27. 27.
    Dixon JB, Chuang LM, Chong K, Chen SC, Lambert GW, Straznicky NE, Lambert EA, Lee WJ. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36:20–6.CrossRefGoogle Scholar
  28. 28.
    Rubino F, Kaplan LM, Schauer PR, Cummings DE. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399–405.CrossRefGoogle Scholar
  29. 29.
    Dixon JB, Zimmet P, Alberti KG, Mbanya JC, Rubino F. Bariatric surgery for diabetes: the International Diabetes Federation takes a position. J Diabetes. 2011;3(4):261–4.CrossRefGoogle Scholar
  30. 30.
    Campos J, Ramos A, Szego T, Zilberstein B, Feitosa H, Cohen R. The role of metabolic surgery for patients with obesity grade I and type 2 diabetes not controlled clinically. Arq Bras Cir Dig. 2016;29:102–6.CrossRefGoogle Scholar
  31. 31.
    Rubino F, Nathan DM, Eckel RH, et al.; 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by the international diabetes organizations. Diabetes Care. 2016;39:861–877.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Jose Guido Correa de AraujoJr.
    • 1
  • Josemberg Marins Campos
    • 1
  • Renata Paiva Barbosa
    • 2
  • Maira Danielle Gomes
    • 1
  • Álvaro Antônio Bandeira Ferraz
    • 3
  1. 1.Surgery DepartmentUniversity Hospital, Pernambuco Federal UniversityRecifeBrazil
  2. 2.Esperança D’Or HospitalRecifeBrazil
  3. 3.Federal University of Pernambuco, Department of SurgeryRecifeBrazil

Personalised recommendations